AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Financial Results | Boston Scientific 2025 Half-Year Revenue USD 9724.00 Million Net Income USD 1467.00 Million
ByAinvest
Wednesday, Jul 23, 2025 8:00 am ET1min read
Boston Scientific(BSX) posted the Q2 of its 2025 financial results on 7/23/2025, reporting total revenue of USD 9724.00 million in the first half of the year, up 21.90% from USD 7977.00 million year over year, reporting net income of USD 1467.00 million in the first half of the year, up 80.00% from USD 815.00 million year over year. The EPS is USD 0.99 in the first half of the year, compare with USD 0.56 last period.
[Detailed Data]
| Million USD | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Total Revenue | 5061.00 | 4663.00 | 4561.00 | 4209.00 |
| Cost of Sales | 1637.00 | 1453.00 | 1466.00 | 1312.00 |
| Gross Profit | 3424.00 | 3210.00 | 3095.00 | 2897.00 |
| Total Operating Expenses | 2695.00 | 2370.00 | 2501.00 | 2243.00 |
| Operating Income | 729.00 | 840.00 | 594.00 | 654.00 |
| Net Income | 795.00 | 672.00 | 562.00 | 468.00 |
| Net Income Attributable to Common Shareholders | 797.00 | 674.00 | 566.00 | 469.00 |
| EPS(USD) | 0.54 | 0.46 | 0.38 | 0.32 |
[Company Profile]
Boston Scientific Corporation's history began in the late 1960s. The company is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. The company's Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with innovative, less invasive technologies.The company's Urology and Pelvic Health business develops and manufactures devices to treat various urological and pelvic conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction, incontinence, pelvic floor disorders, abnormal uterine bleeding and uterine fibroids and polyps. The company's Cardiac Rhythm Management (CRM) business develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The company's Electrophysiology business develops and manufactures less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart, including a broad portfolio of therapeutic and diagnostic catheters and a variety of equipment used in the Electrophysiology lab. The company's Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The company's Interventional Cardiology business develops, manufactures and commercializes technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet